« Back to news listing

Abbott Completes Acquisition of IDEV Technologies

Abbott announced on August 21, 2013 that it completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and interventional cardiologists.

The acquisition expands Abbott’s global peripheral technology portfolio with IDEV Technologies’ SUPERA Veritas® self-expanding nitinol stent system. SUPERA Veritas has CE Mark in Europe for treating blockages in blood vessels due to peripheral artery disease (PAD). In the U.S., SUPERA Veritas is cleared only for the treatment of biliary strictures (narrowing of a bile duct) related to cancer. It is currently being reviewed under a Premarket Approval application by the U.S. Food and Drug Administration for treatment of the superficial femoral artery, which is the main artery in the thigh that supplies blood to lower extremities, and is not currently approved in the U.S. for that use.

Read entire article: http://www.abbott.com/press-release/abbott-completes-acquisition-of-idev-technologies.htm

« Back to news listing